A bioequivalence pivotal study to evaluate TYMLOS

Trial Profile

A bioequivalence pivotal study to evaluate TYMLOS

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Abaloparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 02 Nov 2017 The company has scheduled a meeting with the FDA in January 2018 to align on a regulatory pathway for this trial, as reported in a Radius media release.
    • 04 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top